Coronary Microcirculatory and Bioresorbable Vascular Scaffolds

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
CHD - Coronary Heart DiseaseAngina, StableMyocardial Ischemia
Interventions
DEVICE

Bioresorbable Vascular Scaffolds (BVS)

Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.

DEVICE

Drug-Eluting Stent (DES) - slow

"Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."

DEVICE

Drug-Eluting Stent (DES) - standard(std)

Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.

Trial Locations (1)

CB23 3RE

Papworth Hospital NHS Foundation Trust, Cambridge

All Listed Sponsors
lead

Papworth Hospital NHS Foundation Trust

OTHER_GOV

NCT03076476 - Coronary Microcirculatory and Bioresorbable Vascular Scaffolds | Biotech Hunter | Biotech Hunter